Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Vaxcyte, Inc. | PRESIDENT AND CFO | Common Stock | 109K | $2.29M | $20.93 | Oct 25, 2024 | Direct |
Caribou Biosciences, Inc. | Director | Option to purchase Common Stock | 39.5K | $106K | $2.69 | Feb 20, 2024 | Direct |
Vaxcyte, Inc. | PRESIDENT AND CFO | Stock Option (right to buy) | 126K | Oct 25, 2024 | Direct | ||
Metacrine, Inc. | Director | Stock Option (right to buy) | 16.5K | May 18, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PCVX | Vaxcyte, Inc. | Oct 25, 2024 | 2 | $400K | 4 | Oct 28, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Oct 18, 2024 | 10 | -$4.62M | 4 | Oct 22, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Sep 18, 2024 | 5 | -$885K | 4 | Sep 19, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Sep 3, 2024 | 1 | -$698K | 4 | Sep 5, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Aug 19, 2024 | 4 | -$586K | 4 | Aug 20, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Jul 18, 2024 | 6 | -$607K | 4 | Jul 22, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Jun 18, 2024 | 4 | -$533K | 4 | Jun 20, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | May 20, 2024 | 4 | -$557K | 4 | May 22, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Apr 18, 2024 | 4 | -$447K | 4 | Apr 22, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Mar 18, 2024 | 4 | -$509K | 4 | Mar 20, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Feb 29, 2024 | 3 | -$272K | 4 | Mar 4, 2024 | PRESIDENT AND CFO |
CRBU | Caribou Biosciences, Inc. | Feb 20, 2024 | 1 | $0 | 4 | Feb 22, 2024 | Director |
PCVX | Vaxcyte, Inc. | Feb 20, 2024 | 5 | -$553K | 4 | Feb 22, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Jan 18, 2024 | 6 | -$443K | 4 | Jan 19, 2024 | PRESIDENT AND CFO |
PCVX | Vaxcyte, Inc. | Dec 18, 2023 | 4 | -$439K | 4 | Dec 20, 2023 | President and CFO |
PCVX | Vaxcyte, Inc. | Dec 14, 2023 | 3 | -$768K | 4 | Dec 18, 2023 | President and CFO |
PCVX | Vaxcyte, Inc. | Nov 20, 2023 | 4 | -$366K | 4 | Nov 22, 2023 | President and CFO |
PCVX | Vaxcyte, Inc. | Oct 18, 2023 | 4 | -$325K | 4 | Oct 20, 2023 | President and CFO |
PCVX | Vaxcyte, Inc. | Sep 5, 2023 | 1 | -$182K | 4 | Sep 6, 2023 | President and CFO |
PCVX | Vaxcyte, Inc. | Mar 1, 2023 | 3 | -$71.7K | 4 | Mar 3, 2023 | President and CFO |
CRBU | Caribou Biosciences, Inc. | Feb 21, 2023 | 1 | $0 | 4 | Feb 23, 2023 | Director |
PCVX | Vaxcyte, Inc. | Dec 30, 2022 | 3 | $127K | 4 | Jan 4, 2023 | President and CFO |
PCVX | Vaxcyte, Inc. | Sep 19, 2022 | 4 | -$64.3K | 4 | Sep 21, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Sep 2, 2022 | 1 | -$123K | 4 | Sep 7, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Aug 25, 2022 | 9 | -$815K | 4 | Aug 29, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Aug 18, 2022 | 4 | -$61.7K | 4 | Aug 22, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Jul 18, 2022 | 4 | -$59.5K | 4 | Jul 20, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Jul 8, 2022 | 3 | -$57.8K | 4 | Jul 12, 2022 | President and CFO |
MTCR | Metacrine, Inc. | May 18, 2022 | 1 | $0 | 4 | Sep 6, 2022 | Director |
PCVX | Vaxcyte, Inc. | May 18, 2022 | 4 | -$59.2K | 4 | May 20, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Apr 18, 2022 | 3 | -$58K | 4 | Apr 20, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Mar 18, 2022 | 3 | -$64.4K | 4 | Mar 22, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Mar 2, 2022 | 2 | $0 | 4 | Mar 4, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Mar 1, 2022 | 3 | -$116K | 4 | Mar 3, 2022 | President and CFO |
PCVX | Vaxcyte, Inc. | Dec 23, 2021 | 3 | -$57.8K | 4 | Dec 28, 2021 | President and CFO |
CRBU | Caribou Biosciences, Inc. | Dec 20, 2021 | 1 | $0 | 4 | Dec 21, 2021 | Director |
PCVX | Vaxcyte, Inc. | Nov 18, 2021 | 4 | -$59.4K | 4 | Nov 22, 2021 | President and CFO |
CRBU | Caribou Biosciences, Inc. | Jul 22, 2021 | 0 | $0 | 3 | Jul 22, 2021 | Director |
MTCR | Metacrine, Inc. | May 24, 2021 | 1 | $0 | 4 | May 25, 2021 | Director |